Can senolytic drugs restore fertility in female mice with fatty liver disease?

Metabolic dysfunction-associated liver disease (MASLD, formerly called NAFLD) is increasingly common and can impair reproductive health, especially in aging women. Senescent cells—cells that have stopped dividing but remain metabolically active—accumulate with age and are thought to drive both liver disease and ovarian aging. This study tested whether senolytic drugs (Dasatinib + Quercetin, a combination previously shown to clear senescent cells) could restore fertility in female mice with MASLD.

The researchers fed 3-month-old mice either standard chow or a Western diet (high fat/sugar) until 9 months old to induce MASLD. Starting at 6 months, half the mice in each diet group received senolytic treatment while the other half got placebo. The team then measured liver damage, ovarian health, and reproductive success.

As expected, Western diet mice developed fatty livers with increased inflammation, senescence, and fibrosis—mimicking human MASLD. Pregnancy rates dropped by about 40% in these mice. Senolytic treatment improved pregnancy rates back toward normal and reduced ovarian senescence and inflammation. However, the treatment only modestly improved liver pathology itself (slight reduction in liver mass, some gene expression changes), suggesting the fertility benefit wasn't driven by fixing the liver damage.

A critical limitation is the small sample size (exact N not stated in abstract, but typical for mouse studies: ~8-12 per group), which limits statistical power and raises uncertainty about effect sizes. The study is also in mice, not humans, so translation is uncertain. We don't know the mechanism by which ovarian senescence improved without changes in follicle numbers, or whether the benefit would persist long-term. Additionally, this is the first report of this specific intervention in this disease context—no independent replication yet.

For longevity research, this is an interesting proof-of-concept that senolytics might selectively benefit reproductive aging even when systemic metabolic disease persists. However, the modest liver effects and lack of human data mean this remains experimental. The finding that senescence reduction in the ovary didn't restore follicle numbers also hints that ovarian aging involves mechanisms beyond senescent cell accumulation—an important nuance for future fertility interventions.